Research Papers:

Talin1 targeting potentiates anti-angiogenic therapy by attenuating invasion and stem-like features of glioblastoma multiforme

Wonyoung Kang, Sung Heon Kim, Hee Jin Cho, Juyoun Jin, Jeongwu Lee, Kyeung Min Joo and Do-Hyun Nam _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2015; 6:27239-27251. https://doi.org/10.18632/oncotarget.4835

Metrics: PDF 2159 views  |   HTML 2276 views  |   ?  


Wonyoung Kang1,3, Sung Heon Kim4, Hee Jin Cho2, Juyoun Jin1,3, Jeongwu Lee5, Kyeung Min Joo1,2,4, Do-Hyun Nam2,3

1Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Korea

2Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea

3Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

4Department of Anatomy and Cell Biology, Sungkyunkwan University School of Medicine, Seoul, Korea

5Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA

Correspondence to:

Do-Hyun Nam, e-mail: [email protected]

Kyeung Min Joo, e-mail: [email protected]

Keywords: glioblastoma multiforme, anti-angiogenic therapy, bevacizumab-resistance, Talin1, patient derived xenograft models

Received: April 30, 2015     Accepted: August 07, 2015     Published: August 20, 2015


Glioblastoma multiforme (GBM) possesses florid angiogenesis. However, the anti-angiogenic agent, Bevacizumab, did not improve overall survival of GBM patients. For more durable anti-angiogenic treatment, we interrogated resistant mechanisms of GBM against Bevacizumab. Serial orthotopic transplantation of in vivo Bevacizumab-treated GBM cells provoked complete refractoriness to the anti-angiogenic treatment. These tumors were also highly enriched with malignant phenotypes such as invasiveness, epithelial to mesenchymal transition, and stem-like features. Through transcriptome analysis, we identified that Talin1 (TLN1) significantly increased in the refractory GBMs. Inhibition of TLN1 not only attenuated malignant characteristics of GBM cells but also reversed the resistance to the Bevacizumab treatment. These data implicate TLN1 as a novel therapeutic target for GBM to overcome resistance to anti-angiogenic therapies.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4835